{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:48Z","timestamp":1794893628502,"version":"4.9.1"},"reference-count":104,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over 30 countries as monotherapy for DLBCL after two prior treatment lines; odronextamab has recent European approval, and mosunetuzumab is active and is being developed as a combination partner. These agents can be safely combined with other immunotherapies and chemotherapy, and single-arm and randomized trial outcomes promise an expanding role for this class of drugs in earlier treatment lines. This review examines the clinical development of the CD20xCD3 bispecific antibodies in DLBCL, how the phase I and II trials inform their current use, and the key distinctions between the agents. We focus on the efficacy and safety of those bispecific antibodies most advanced in development. We also consider emerging understandings of resistance mechanisms. Finally, we review key ongoing trials and combinations and consider the potential future of bispecific antibodies within the sequence of available treatments for DLBCL.<\/jats:p>","DOI":"10.3324\/haematol.2024.285343","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:42:12Z","timestamp":1738813332000},"page":"1483-1499","source":"Crossref","is-referenced-by-count":23,"title":["New bispecific antibodies in diffuse large B-cell lymphoma"],"prefix":"10.3324","volume":"110","author":[{"given":"Adrian G.","family":"Minson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"76183","doi-asserted-by":"crossref","unstructured":"Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021; 39(18):1959-1970.","DOI":"10.1200\/JCO.20.03175"},{"key":"76184","doi-asserted-by":"crossref","unstructured":"Smith EJ, Olson K, Haber LJ. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015; 5:17943.","DOI":"10.1038\/srep17943"},{"key":"76185","doi-asserted-by":"crossref","unstructured":"Hutchings M, Mous R, Clausen MR. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021; 398(10306):1157-1169.","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"76186","doi-asserted-by":"crossref","unstructured":"Bacac M, Colombetti S, Herter S. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018; 24(19):4785-4797.","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"76187","doi-asserted-by":"crossref","unstructured":"Bray JS, Thomas GR, Smith VM, Jayne S, Dyer MJS, Walter HS. Comparative in-vitro efficacy of CD20xCD3 IgG bispecific biosimilar constructs against diffuse large B cell lymphoma (DLBCL) cell lines with different levels of expression of CD20. Blood. 2024; 144(Supplement 1):5826.","DOI":"10.1182\/blood-2024-203884"},{"key":"76188","doi-asserted-by":"crossref","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020; 52:102625.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"76189","doi-asserted-by":"crossref","unstructured":"Li T, Hiemstra IH, Chiu C. Semimechanistic physiologically-based pharmacokinetic\/pharmacodynamic model informing epcoritamab dose selection for patients with B-cell lymphomas. Clin Pharmacol Ther. 2022; 112(5):1108-1119.","DOI":"10.1002\/cpt.2729"},{"key":"76190","doi-asserted-by":"crossref","unstructured":"Bannerji R, Arnason JE, Advani RH. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5):e327-e339.","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"76191","doi-asserted-by":"crossref","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014; 3(10):e144.","DOI":"10.1038\/psp.2014.42"},{"key":"76192","doi-asserted-by":"crossref","unstructured":"Djebli N, Jaminion F, Laurent J. Population pharmacokinetics and novel exposure-response analyses to inform optimal biologic dose selection for CD20-TCB, a T-cell-engaging bispecific antibody, in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2019; 134(Supplement 1):3799.","DOI":"10.1182\/blood-2019-123712"},{"key":"76193","doi-asserted-by":"crossref","unstructured":"Topp MS, Gokbuget N, Zugmaier G. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36):4134-4140.","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"76194","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"76195","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Morschhauser F, Iacoboni G. CD20\u2010TCB (RG6026), a novel \u201c2:1\u201d format T\u2010cell\u2010engaging bispecific antibody, induces complete remissions in relapsed\/refractory B\u2010cell non\u2010Hodgkin\u2019s lymphoma. Hematol Oncol. 2019; 37(S2):92-93.","DOI":"10.1002\/hon.59_2629"},{"key":"76196","doi-asserted-by":"crossref","unstructured":"Hutchings M, Ahmadi T, Gupta M. First-in-human, phase 1\/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody\u00ae-CD3\u00d7CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019; 134(Supplement 1):758.","DOI":"10.1182\/blood-2019-121460"},{"key":"76197","doi-asserted-by":"crossref","unstructured":"Zhu M, Ambati SR, Mohamed H. Modeling and simulation in support of odronextamab subcutaneous dose selection for adult patients with indolent or aggressive non-Hodgkin lymphoma. Blood. 2022; 140(Supplement 1):11579-11580.","DOI":"10.1182\/blood-2022-158409"},{"key":"76198","doi-asserted-by":"crossref","unstructured":"Sesques P, Houot R, Al Tabaa Y. Glofitamab monotherapy in patients with non-Hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the Bicar study, a phase II Lysa study. Blood. 2023; 142(Supplement 1):893.","DOI":"10.1182\/blood-2023-177703"},{"key":"76199","doi-asserted-by":"crossref","unstructured":"Falchi L, Carlo-Stella C, Morschhauser F. Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL). Blood. 2023; 142(Supplement 1):3130.","DOI":"10.1182\/blood-2023-173949"},{"key":"76200","doi-asserted-by":"crossref","unstructured":"Vose JM, Feldman T, Chamuleau MED. Mitigating the risk of cytokine release syndrome (CRS): preliminary results from a DLBCL cohort of Epcore NHL-1. Blood. 2023; 142(Supplement 1):1729.","DOI":"10.1182\/blood-2023-180333"},{"key":"76201","doi-asserted-by":"crossref","unstructured":"Crombie JL, Graff T, Falchi L. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024; 143(16):1565-1575.","DOI":"10.1182\/blood.2023022432"},{"key":"76202","doi-asserted-by":"crossref","unstructured":"Blair HA. Odronextamab: first approval. Drugs. 2024; 84(12):1651-1658.","DOI":"10.1007\/s40265-024-02112-6"},{"key":"76203","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24):2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"76204","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Phillips T, Ghesquieres H. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023; 41(12):2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"76205","doi-asserted-by":"crossref","unstructured":"Ayyappan S, Kim WS, Kim TM. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/ refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2023; 142(Supplement 1):436.","DOI":"10.1182\/blood-2023-179818"},{"key":"76206","doi-asserted-by":"crossref","unstructured":"Iskierka-Jazdzewska E, Kim WS, Cho S-G. Health-related quality of life and symptoms in patients with relapsed or refractory diffuse large B-cell lymphoma treated with odronextamab monotherapy in the phase 2 ELM-2 study. Blood. 2023; 142(Supplement 1):4504.","DOI":"10.1182\/blood-2023-180743"},{"key":"76207","doi-asserted-by":"crossref","unstructured":"Allan JN, Crombie JL, Matasar M. Long-term efficacy and safety of odronextamab in relapsed\/refractory diffuse large B-cell lymphoma (DLBCL): pooled analysis from the ELM-1 and ELM-2 studies. Blood. 2024; 144(Supplement 1):3118.","DOI":"10.1182\/blood-2024-199980"},{"key":"76208","doi-asserted-by":"crossref","unstructured":"Bartlett NL, Assouline S, Giri P. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/ refractory diffuse large B-cell lymphoma. Blood Adv. 2023; 7(17):4926-4935.","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"76209","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonzalez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"76210","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Hutchings M, Morschhauser F. BP43131, a phase 1 dose escalation study: CD19 targeted CD28 costimulatory agonist (RO7443904) combined with glofitamab shows promising efficacy in patients with relapsed\/refractory aggressive B-NHL. Blood. 2024; 144(Supplement 1):3123.","DOI":"10.1182\/blood-2024-205544"},{"key":"76211","doi-asserted-by":"crossref","unstructured":"Karimi Y, Thieblemont C, Ghesquieres H. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: subcutaneous epcoritamab monotherapy in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL). J Clin Oncol. 2024; 42:7039.","DOI":"10.1200\/JCO.2024.42.16_suppl.7039"},{"key":"76212","doi-asserted-by":"crossref","unstructured":"Hutchings M, Carlo-Stella C, Morschhauser F. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. Blood. 2023; 142(Supplement 1):433.","DOI":"10.1182\/blood-2023-173951"},{"key":"76213","doi-asserted-by":"crossref","unstructured":"Matasar M, Crombie J, Topp M. Odronextamab demonstrates durable complete responses in patients with diffuse large B-cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study. Hemasphere. 2024; 8:2128.","DOI":"10.1182\/blood-2023-181602"},{"key":"76214","doi-asserted-by":"crossref","unstructured":"Rejeski K, Subklewe M, Aljurf M. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877.","DOI":"10.1182\/blood.2023020578"},{"key":"76215","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"76216","doi-asserted-by":"crossref","unstructured":"Gritti G, Belousov A, Relf J, Dixon M, Tandon M, Komanduri K. Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma. Blood Adv. 2024; 8(14):3615-3618.","DOI":"10.1182\/bloodadvances.2023011089"},{"key":"76217","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Karimi YH, Cheah CY. Three-factor prediction model for grade 2+ cytokine release syndrome in large B-cell lymphoma patients receiving epcoritamab monotherapy. Blood. 2024; 144(Supplement 1):4491.","DOI":"10.1182\/blood-2024-200957"},{"key":"76218","doi-asserted-by":"crossref","unstructured":"Reynolds GK, Maclean M, Cliff ERS. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv. 2024; 8(13):3555-3559.","DOI":"10.1182\/bloodadvances.2024012916"},{"key":"76219","doi-asserted-by":"crossref","unstructured":"Abramson JS, Ku M, Hertzberg M. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024; 404(10466):1940-1954.","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"76220","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Sehn LH, Bartlett NL. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023; 142(Supplement 1):603.","DOI":"10.1182\/blood-2023-173692"},{"key":"76221","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. Blood. 2024; 144(Supplement 1):865.","DOI":"10.1182\/blood-2024-194333"},{"key":"76222","doi-asserted-by":"crossref","unstructured":"Falchi L, Rahman J, Melendez L. Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas. medRxiv. 2024. Publisher Full Text|","DOI":"10.1101\/2024.07.02.24309792"},{"key":"76223","doi-asserted-by":"crossref","unstructured":"Brouwer-Visser J, Fiaschi N, Deering RP. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. J Immunother Cancer. 2024; 12(3):e008338.","DOI":"10.1136\/jitc-2023-008338"},{"key":"76224","doi-asserted-by":"crossref","unstructured":"Broske AE, Korfi K, Belousov A. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/ refractory non-Hodgkin lymphoma. Blood Adv. 2022; 6(3):1025-1037.","DOI":"10.1182\/bloodadvances.2021005954"},{"key":"76225","doi-asserted-by":"crossref","unstructured":"Nassiri S, Schmeing S, Leclercq G. Molecular mechanisms underlying response and resistance to glofitamab. Blood. 2023; 142(Supplement 1):1619.","DOI":"10.1182\/blood-2023-179776"},{"key":"76226","unstructured":"Zhang J, Wielgos-Bonvallet M, Si H. Immune correlates of response to epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma: dose expansion in a phase 1\/2 trial. Hemasphere. 2023; 8(S1):P1244."},{"key":"76227","unstructured":"Luminari S, Brouwer-Visser J, Fiaschi N. CD20 expression and response to odronextamab: biomarker analysis in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL) from the ELM-2 study. Hemasphere. 2024; 8:2295."},{"key":"76228","doi-asserted-by":"crossref","unstructured":"Grigg S, Minson A, Prins E, Dickinson MJ. Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high. Br J Haematol. 2024; 205(1):122-126.","DOI":"10.1111\/bjh.19455"},{"key":"76229","doi-asserted-by":"crossref","unstructured":"Duell J, Leipold AM, Appenzeller S. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. Blood. 2024; 143(8):685-696.","DOI":"10.1182\/blood.2023021672"},{"key":"76230","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Huw LY, Bolen CR. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/ refractory B-cell lymphomas. Blood. 2024; 143(9):822-832.","DOI":"10.1182\/blood.2023022348"},{"key":"76231","unstructured":"Devata S, Gaballa S, Nair R. AZD0486, a novel CD19xCD3 T-cell engager, shows durable responses in patients with relapsed\/refractory follicular lymphoma: update on efficacy and safety. Hemasphere. 2024; 8(S1):2059."},{"key":"76232","doi-asserted-by":"crossref","unstructured":"Kuchnio A, Yang D, Vloemans N. Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma. Blood. 2022; 140(Supplement 1):3105-3106.","DOI":"10.1182\/blood-2022-168739"},{"key":"76233","unstructured":"Carlo-Stella C, Leung W, Dickinson M. Response in molecular subgroups and circulating tumor (ct)DNA kinetics in patients with relapsed and\/or refractory (R\/R) large B-cell lymphoma (LBCL) treated with glofitamab monotherapy. Hemasphere. 2024; 8(S1):2281."},{"key":"76234","doi-asserted-by":"crossref","unstructured":"Falchi L, Clausen M, Offner F. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: updated EPCORE NHL-2 data. J Clin Oncol. 2023; 41(16S):7519.","DOI":"10.1200\/JCO.2023.41.16_suppl.7519"},{"key":"76235","unstructured":"Tucker D, Arnason JE, Brouwer-Visser J. Circulating tumor DNA analysis associates with PFS with odronextamab monotherapy in R\/R FL and DLBCL: identification of MRD status and high-risk subgroups from the phase 2 ELM-2 study. Hemasphere. 2024; 8(S1):2264."},{"key":"76236","doi-asserted-by":"crossref","unstructured":"Soong D, Alt\u0131nta\u015f I, Karavitis J. Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed\/refractory follicular lymphoma (R\/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1\/2 EPCORE(TM) NHL-1 trial. Cancer Res. 2024; 84(6S):5071.","DOI":"10.1158\/1538-7445.AM2024-5071"},{"key":"76237","doi-asserted-by":"crossref","unstructured":"Falchi L, Jardin F, Haioun C. Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: preliminary safety and efficacy results. Blood. 2023; 142(Supplement 1):858.","DOI":"10.1182\/blood-2023-173953"},{"key":"76238","doi-asserted-by":"crossref","unstructured":"Budde LE, Olszewski AJ, Assouline S. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial. Nat Med. 2024; 30(1):229-239.","DOI":"10.1038\/s41591-023-02726-5"},{"key":"76239","doi-asserted-by":"crossref","unstructured":"Hutchings M, Avigdor A, Sureda Balari AM. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with \u22652L relapsed\/refractory DLBCL, including HGBCL, and in patients with prior CAR T-cell therapy: updated results from a phase Ib\/II study. Blood. 2023; 142(Supplement 1):4460.","DOI":"10.1182\/blood-2023-174213"},{"key":"76240","doi-asserted-by":"crossref","unstructured":"Westin J, Olszewski AJ, Fogliatto L. SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. J Clin Oncol. 2023; 41(16_suppl):TPS7586.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7586"},{"key":"76241","doi-asserted-by":"crossref","unstructured":"Brody J, Joergensen JM, Belada D. Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: updated results from Epcore NHL-2. Blood. 2023; 142(Supplement 1):3092.","DOI":"10.1182\/blood-2023-180246"},{"key":"76242","doi-asserted-by":"crossref","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules. 2022; 12(9):1303.","DOI":"10.3390\/biom12091303"},{"key":"76243","unstructured":"Claus C, Ferrara C, Xu W. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019; 11(496)"},{"key":"76244","doi-asserted-by":"crossref","unstructured":"Sam J, Hofer T, Kuettel C. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. Blood. 2024; 143(21):2152-2165.","DOI":"10.1182\/blood.2023023381"},{"key":"76245","doi-asserted-by":"crossref","unstructured":"Wei J, Montalvo-Ortiz W, Yu L. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Sci Transl Med. 2022; 14(670):eabn1082.","DOI":"10.1126\/scitranslmed.abn1082"},{"key":"76246","doi-asserted-by":"crossref","unstructured":"Hutchings M, Dickinson MJ, Gritti G. Englumafusp alfa (CD19-4-1BBL) Combined with glofitamab is safe and efficacious in patients with r\/r B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072. Blood. 2024; 144(Supplement 1):990.","DOI":"10.1182\/blood-2024-200096"},{"key":"76247","doi-asserted-by":"crossref","unstructured":"Avivi Mazza I, Kim WS, Ko P-S. Subcutaneous epcoritamab plus lenalidomide in patients with relapsed\/refractory diffuse large B-cell lymphoma from EPCORE NHL-5. Blood. 2023; 142(Supplement 1):438.","DOI":"10.1182\/blood-2023-180089"},{"key":"76248","doi-asserted-by":"crossref","unstructured":"Carpio C, Namuduri M, Iqbal N. Trial in progress: phase 1 trial evaluating the safety and tolerability of odronextamab in combination with cemiplimab in relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Blood. 2023; 142(Supplement 1):3100.","DOI":"10.1182\/blood-2023-179964"},{"key":"76249","doi-asserted-by":"crossref","unstructured":"Hutchings M, Gritti G, Sureda A. CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2019; 134(Supplement 1):2871.","DOI":"10.1182\/blood-2019-123978"},{"key":"76250","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Bartlett NL. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019; 20(7):998-1010.","DOI":"10.1016\/S1470-2045(19)30091-9"},{"key":"76251","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024; 38(12):2653-2662.","DOI":"10.1038\/s41375-024-02410-8"},{"key":"76252","doi-asserted-by":"crossref","unstructured":"Westin JR, Oluwole OO, Kersten MJ. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023; 389(2):148-157.","DOI":"10.1056\/NEJMoa2301665"},{"key":"76253","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason JE. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 Transform study. Blood. 2021; 138(Supplement 1):91.","DOI":"10.1182\/blood-2021-147913"},{"key":"76254","doi-asserted-by":"crossref","unstructured":"Houot R, Bachy E, Cartron G. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023; 29(10):2593-2601.","DOI":"10.1038\/s41591-023-02572-5"},{"key":"76255","doi-asserted-by":"crossref","unstructured":"Ababneh HS, Ng AK, Frigault MJ. Salvage radiotherapy in relapsed\/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 2023; 108(11):2972-2981.","DOI":"10.3324\/haematol.2023.282804"},{"key":"76256","doi-asserted-by":"crossref","unstructured":"Melody M, Grover N, Franco S. Efficacy, toxicity, and predictors of outcomes with CD3-CD20 bi-specific antibodies post CAR T-cell failure for aggressive B-cell lymphoma. Blood. 2024; 144(Supplement 1):473.","DOI":"10.1182\/blood-2024-201626"},{"key":"76257","doi-asserted-by":"crossref","unstructured":"Shumilov E, Wurm-Kuczera R, Vucinic V. Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed\/refractory large B-cell lymphoma. Blood. 2024; 144(Supplement 1):114.","DOI":"10.1182\/blood-2024-198883"},{"key":"76258","doi-asserted-by":"crossref","unstructured":"Braun A, Schuster SJ, Nastoupil L. Efficacy and safety outcomes of CAR T-cell therapies in patients with relapsed\/ refractory B-cell non-Hodgkin lymphoma who received prior treatment with mosunetuzumab. Blood. 2024; 144(Supplement 1):6555.","DOI":"10.1182\/blood-2024-198409"},{"key":"76259","doi-asserted-by":"crossref","unstructured":"Crochet G, Iacoboni G, Couturier A. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024; 144(3):334-338.","DOI":"10.1182\/blood.2024024526"},{"key":"76260","doi-asserted-by":"crossref","unstructured":"Vose JM, Cheah CY, Clausen MR. 3-year update from the Epcore NHL-1 trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. Blood. 2024; 144(Supplement 1):4480.","DOI":"10.1182\/blood-2024-198714"},{"key":"76261","doi-asserted-by":"crossref","unstructured":"Topp MS, Tani M, Dickinson M. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase Ib study. Blood. 2023; 142(Supplement 1):3085.","DOI":"10.1182\/blood-2023-174081"},{"key":"76262","doi-asserted-by":"crossref","unstructured":"Dickinson M, Viardot A, Marks R. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study. J Clin Oncol. 2023; 41(16S):7549.","DOI":"10.1200\/JCO.2023.41.16_suppl.7549"},{"key":"76263","doi-asserted-by":"crossref","unstructured":"Minson A, Verner E, Giri P. Glofitamab plus R\u2010CHOP or polatuzumab vedotin\u2010R\u2010CHP is deliverable with high overall response in patients \u226465 years of age with high\u2010risk DLBCL: interim analysis of COALITION. Hematol Oncol. 2023; 41(S2):421-422.","DOI":"10.1002\/hon.3164_309"},{"key":"76264","doi-asserted-by":"crossref","unstructured":"Minson A, Verner E, Giri P. A randomized phase 2, investigator-led trial of glofitamab-R-CHOP or glofitamab-polatuzumab vedotin-R-CHP (COALITION) in younger patients with high burden, high-risk large B-cell lymphoma demonstrates safety, uncompromised chemotherapy intensity, a high rate of durable remissions, and unique FDG-PET response characteristics. Blood. 2024; 144(Supplement 1):582.","DOI":"10.1182\/blood-2024-204930"},{"key":"76265","doi-asserted-by":"crossref","unstructured":"Falchi L, Offner F, de Vos S. Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: long-term results from the Epcore NHL-2 trial. Blood. 2024; 144(Supplement 1):581.","DOI":"10.1182\/blood-2024-198023"},{"key":"76266","doi-asserted-by":"crossref","unstructured":"Kerr DA, Lavie D, Avigdor A. First data from subcutaneous epcoritamab + polatuzumab vedotin rituximab, cyclophosphamide doxorubicin, and prednisone (Pola-RCHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5. Clin Lymphoma Myeloma Leuk. 2024; 24(Supplement 1):S478-S479.","DOI":"10.1016\/S2152-2650(24)01527-1"},{"key":"76267","doi-asserted-by":"crossref","unstructured":"Olszewski AJ, Phillips TJ, Hoffmann MS. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023; 7(20):6055-6065.","DOI":"10.1182\/bloodadvances.2023010840"},{"key":"76268","doi-asserted-by":"crossref","unstructured":"Olszewski AJ, Eradat H, Avigdor A. Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large B-cell lymphoma. Blood. 2023; 142(Supplement 1):855.","DOI":"10.1182\/blood-2023-177588"},{"key":"76269","doi-asserted-by":"crossref","unstructured":"Melchardt T, Wurm-Kuczera RI, Altmann B. Feasibility and safety of the first-in-human chemotherapy-light combination of rituximab, polatuzumab vedotin and glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP - R-Pola-Glo\/Ikf-t062, a study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10). Blood. 2023; 142(Supplement 1):1734.","DOI":"10.1182\/blood-2023-188854"},{"key":"76270","unstructured":"Wurm-Kuczera R, Melchardt T, Altmann B. Feasibility and safety data of the chemotherapy-light combination of rituximab, polatuzumab vedotin and glofitamab in aggressive B-cell lymphoma patients ineligible for fully dosed R-CHOP. EHA 2024 Hybrid Congress."},{"key":"76271","doi-asserted-by":"crossref","unstructured":"Vermaat JSP, Brody J, \u010eura\u0161 J. Epcoritamab SC + R-mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: first disclosure from arm 8 of the Epcore NHL-2 trial. Blood. 2023; 142(Supplement 1):4457.","DOI":"10.1182\/blood-2023-180935"},{"key":"76272","doi-asserted-by":"crossref","unstructured":"Leslie LA, Cheah CY, Morschhauser F. Fixed-duration epcoritamab + R-mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: updated results from arm 8 of the Epcore NHL-2 trial. Blood. 2024; 144(Supplement 1):3106.","DOI":"10.1182\/blood-2024-199652"},{"key":"76273","doi-asserted-by":"crossref","unstructured":"Karimi Y, Abrisqueta P, de Vos S. Epcoritamab + R-DHAX\/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2024; 42(16_suppl):7032.","DOI":"10.1200\/JCO.2024.42.16_suppl.7032"},{"key":"76274","doi-asserted-by":"crossref","unstructured":"Cordoba R, J\u00f8rgensen J, Belada D. ABCL-275 epcoritamab + GemOx induces deep durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL): updated results from EPCORE NHL-2. Clin Lymphoma Myeloma Leuk. 2024; 24(Supplement 1):S468-S469.","DOI":"10.1016\/S2152-2650(24)01509-X"},{"key":"76275","doi-asserted-by":"crossref","unstructured":"Diefenbach CS, Caimi PF, Saba NS. Glofitamab in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with relapsed or refractory diffuse large B-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy: results from a phase Ib study. Blood. 2024; 144(Supplement 1):987.","DOI":"10.1182\/blood-2024-198452"},{"key":"76276","doi-asserted-by":"crossref","unstructured":"Hutchings M, Sureda Balari A, Bosch F. Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): extended follow-up of a phase Ib\/II study. Blood. 2024; 144(Supplement 1):988.","DOI":"10.1182\/blood-2024-194328"},{"key":"76277","doi-asserted-by":"crossref","unstructured":"Koh Y Byun JM, Hong J. Glofitamab combined with poseltinib and lenalidomide for relapsed\/refractory diffuse large B cell lymphoma: interim analysis of GPL study. J Clin Oncol. 2024; 42(16_suppl):7066.","DOI":"10.1200\/JCO.2024.42.16_suppl.7066"},{"key":"76278","doi-asserted-by":"crossref","unstructured":"Matasar M, Turgut B, Tessoulin B. Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3). J Clin Oncol. 2024; 42(16S):TPS7086.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7086"},{"key":"76279","doi-asserted-by":"crossref","unstructured":"Sehn LH, Chamuleau M, Lenz G. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2. J Clin Oncol. 2023; 41(16S):TPS7592.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7592"},{"key":"76280","doi-asserted-by":"crossref","unstructured":"Advani RH, Dickinson MJ, Fox CP. SKYGLO: a global phase III randomized study evaluating glofitamab plus polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma (LBCL). Blood. 2024; 144(Supplement 1):1718.1.","DOI":"10.1182\/blood-2024-194000"},{"key":"76281","doi-asserted-by":"crossref","unstructured":"Modi D, Kim S, Domagalski M, Mittal V. A phase II investigator-initiated trial of epcoritamab with gemcitabine, dexamethasone, and cisplatin (GDP) salvage chemotherapy in relapsed refractory large B-cell lymphoma. Blood. 2024; 144(Supplement 1):1742.","DOI":"10.1182\/blood-2024-211276"},{"key":"76282","doi-asserted-by":"crossref","unstructured":"Kim K, Chihara D, Fayad LE. Phase II trial of axicabagene ciloleucel and glofitamab as second-line therapy for patients with relapsed or refractory large B-cell lymphoma. Blood. 2024; 144(Supplement 1):4511.","DOI":"10.1182\/blood-2024-205196"},{"key":"76283","doi-asserted-by":"crossref","unstructured":"Dickinson M, Gritti G, Carlo-Stella C. Phase 1 study of CD19 targeted CD28 costimulatory agonist in combination with glofitamab to enhance T cell effector function in relapsed\/ refractory B cell lymphoma. Blood. 2022; 140(Supplement 1):3818-3820.","DOI":"10.1182\/blood-2022-156808"},{"key":"76284","doi-asserted-by":"crossref","unstructured":"Luscan G, Paccagnella L, Patel K. A multicenter, open-label, phase 1b\/2 study to evaluate the effects of maplirpacept in combination with glofitamab in people with relapsed or refractory diffuse large B cell lymphoma. Blood. 2023; 142(Supplement 1):6250.","DOI":"10.1182\/blood-2023-182275"},{"key":"76285","doi-asserted-by":"crossref","unstructured":"Mutsaers PGNJ, Abramson JS, Namuduri M. Trial in progress: Athena-1 \u2013 a phase 1 study to assess safety and tolerability of Regn5837 in combination with odronextamab in patients with relapsed\/refractory aggressive B-cell non-Hodgkin Lymphoma. Hemasphere. 2023; 7(S3):PB2328.","DOI":"10.1097\/01.HS9.0000976032.70825.65"},{"key":"76286","doi-asserted-by":"crossref","unstructured":"Kambhampati S, Kallam A, Borogovac A. A phase 2 study of loncastuximab tesirine plus mosunetuzumab in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2024; 144(Supplement 1):1742.1.","DOI":"10.1182\/blood-2024-198727"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11929\/78065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11929\/78509","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11929\/78065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:10Z","timestamp":1794046090000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":104,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285343","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}